Bacterial Infections, AMR, and Sepsis

Bacterial infections remain one of the leading causes of death globally—not because we lack antibiotics, but because we are treating the problem too late and too narrowly.

At the center of this challenge are pathogen-associated molecular patterns (PAMPs)—structural components of bacteria such as peptidoglycan (PGN), lipoteichoic acid (LTA), and lipopolysaccharide (LPS). These molecules are the primary triggers of the human immune response. When released into circulation, they activate innate immune pathways that drive inflammation, organ dysfunction, and, in severe cases, death. 

Current therapies do not target these upstream drivers. Instead, they either:

• Attempt to kill bacteria (antibiotics), or
• Suppress the downstream consequences of inflammation

Neither approach addresses the root cause: the persistent presence of inflammatory microbial signals.

Antibiotics transformed medicine in the 20th century. In the 21st, they are failing—both biologically and economically.

Biologically, resistance is inevitable. Bacteria evolve rapidly, rendering even the most advanced antibiotics ineffective over time. Today:

• Over 1.2 million deaths annually are directly attributable to antimicrobial resistance
• This number is projected to reach 10 million deaths per year by 2050

Economically, the antibiotic market is broken:

• New antibiotics are intentionally underused due to stewardship programs
• Hospitals are financially disincentivized to adopt expensive therapies under DRG reimbursement
• Even successful companies have failed commercially after approval

The result is a paradox: we can develop new antibiotics, but we cannot sustain them as a business model. 

Sepsis is where bacterial infection, immune activation, and systemic failure converge.

• ~49 million cases globally each year
• ~11 million deaths annually
• $38–62 billion in U.S. healthcare costs alone 

Despite decades of research and over 150 failed clinical trials, no adjunctive therapy beyond antibiotics and supportive care has succeeded.

Why?

Because sepsis is not simply an infection—it is an immune-driven disease triggered by PAMPs. By the time patients present clinically:

• Bacterial products are already circulating
• The immune system is fully activated
• Downstream cytokine cascades are difficult to control

Killing bacteria at this stage does not eliminate the inflammatory signals already driving organ damage.

To solve bacterial disease, we must move upstream.

PAMPs represent a universal, pathogen-agnostic target:

• They are conserved across bacteria (Gram-positive, Gram-negative, mycobacterial)
• They are continuously shed, even during antibiotic treatment
• They are the direct activators of the immune system’s inflammatory pathways 

Targeting PAMPs enables a fundamentally different strategy:

• Neutralize inflammatory triggers before immune activation
• Enhance immune clearance of bacteria through opsonization
• Remain effective regardless of antibiotic resistance

This approach is independent of resistance mechanisms such as efflux pumps, enzymatic degradation, or target mutation—meaning it works against:

• MRSA
• VRE
• CRE
• Drug-resistant tuberculosis
• Multidrug-resistant Gram-negative pathogens